SUBSCRIBE: Print / eNewsletter
A phase III trial of idelalisib plus rituximab in patients with previously treated chronic lymphocytic leukemia found that the combo improved progression-free and overall survival, according to results presented at the 2013 ASH meeting.
In a study presented at the 2013 ASH meeting, researchers showed evidence that p53 mutations are already present in patients who develop treatment-related MDS and AML, results which could help identify high-risk patients prior to cytotoxic therapy.
Treatment with gemtuzumab ozogamicin improved the event-free survival in children and adolescents with acute myeloid leukemia by reducing the risk of relapse among those able to achieve remission, according to trial results presented at the 2013 ASH meeting.
In a 12-patient multiple myeloma pilot study, researchers demonstrated that anti-CD3 and anti-CD20 bispecific antibody (CD20Bi) activated both cellular and humoral anti-myeloma immunity that was detectable after patients received an autologous stem cell transplant.
In a late-breaking abstract presentation, Thorsten Klampfl, PhD, of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, presented data from a whole exome study of primary myelofibrosis patients, identifying a new specific molecular mutation
In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.
Patients with the rare and potentially deadly multicentric Castleman disease were able to achieve durable tumor and symptomatic response when assigned to treatment with the monoclonal antibody siltuximab, according to data presented at the 2013 ASH meeting.
The combination of lenalidomide plus dexamethasone demonstrated an improvement in both response rate and survival in newly diagnosed multiple myeloma patients not eligible for a stem cell transplant, according to data presented at the 2013 ASH meeting.
Patients aged 70 years or older had similar survival outcomes compared to their younger counterparts when undergoing nonmyeloablative, related haploidentical bone marrow or peripheral blood stem cell transplants for the treatment of hematologic malignancies, according to the results of a study presented at the 2013 ASH meeting.
In a front-line trial of older patients with newly diagnosed chronic lymphocytic leukemia, obinutuzumab topped rituximab, demonstrating improvements in response rate and progression-free survival, according to results presented at the ASH annual meeting.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
